16.18 USD
+0.27 (+1.7%)
16.1 USD
-0.08 (-0.49%)
AUPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. AUPH has an excellent financial health rating, but there are some minor concerns on its profitability. AUPH has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes AUPH very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
AUPH had positive earnings in the past year.
In the past year AUPH had a positive cash flow from operations.
In the past 5 years AUPH reported 4 times negative net income.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
AUPH has a better Return On Assets (14.76%) than 95.27% of its industry peers.
The Return On Equity of AUPH (21.28%) is better than 96.60% of its industry peers.
AUPH has a Return On Invested Capital of 14.89%. This is amongst the best in the industry. AUPH outperforms 95.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROIC | 14.89% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of AUPH (29.28%) is better than 95.46% of its industry peers.
The Operating Margin of AUPH (32.73%) is better than 96.79% of its industry peers.
AUPH has a better Gross Margin (88.93%) than 90.74% of its industry peers.
In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUPH has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, AUPH has less shares outstanding
The number of shares outstanding for AUPH has been increased compared to 5 years ago.
AUPH has a better debt/assets ratio than last year.
2.2 Solvency
AUPH has an Altman-Z score of 7.37. This indicates that AUPH is financially healthy and has little risk of bankruptcy at the moment.
AUPH has a better Altman-Z score (7.37) than 78.07% of its industry peers.
AUPH has a debt to FCF ratio of 0.60. This is a very positive value and a sign of high solvency as it would only need 0.60 years to pay back of all of its debts.
The Debt to FCF ratio of AUPH (0.60) is better than 94.90% of its industry peers.
AUPH has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.15, AUPH is doing worse than 65.60% of the companies in the same industry.
Although AUPH does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 7.37 |
ROIC/WACC1.95
WACC7.63%
2.3 Liquidity
A Current Ratio of 5.76 indicates that AUPH has no problem at all paying its short term obligations.
The Current ratio of AUPH (5.76) is comparable to the rest of the industry.
A Quick Ratio of 5.17 indicates that AUPH has no problem at all paying its short term obligations.
AUPH's Quick ratio of 5.17 is in line compared to the rest of the industry. AUPH outperforms 58.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
AUPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 609.09%, which is quite impressive.
Looking at the last year, AUPH shows a very strong growth in Revenue. The Revenue has grown by 20.62%.
AUPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 279.17% yearly.
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
3.2 Future
The Earnings Per Share is expected to grow by 70.13% on average over the next years. This is a very strong growth
Based on estimates for the next years, AUPH will show a quite strong growth in Revenue. The Revenue will grow by 14.93% on average per year.
EPS Next Y743.2%
EPS Next 2Y218.19%
EPS Next 3Y124.5%
EPS Next 5Y70.13%
Revenue Next Year18.56%
Revenue Next 2Y16.97%
Revenue Next 3Y15.79%
Revenue Next 5Y14.93%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AUPH is valuated quite expensively with a Price/Earnings ratio of 28.89.
Compared to the rest of the industry, the Price/Earnings ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 92.82% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.38. AUPH is around the same levels.
With a Price/Forward Earnings ratio of 17.76, AUPH is valued on the expensive side.
AUPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 94.90% of the companies in the same industry.
AUPH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.89 | ||
| Fwd PE | 17.76 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AUPH is valued cheaply inside the industry as 95.09% of the companies are valued more expensively.
95.46% of the companies in the same industry are more expensive than AUPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.8 | ||
| EV/EBITDA | 14.46 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 124.50% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y218.19%
EPS Next 3Y124.5%
5. Dividend
5.1 Amount
No dividends for AUPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
16.18
+0.27 (+1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners50.74%
Inst Owner Change10.72%
Ins Owners1.92%
Ins Owner Change-0.55%
Market Cap2.13B
Revenue(TTM)265.81M
Net Income(TTM)77.84M
Analysts81.54
Price Target17.05 (5.38%)
Short Float %6.91%
Short Ratio5.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.94%
Min EPS beat(2)6.95%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)66.5%
Min EPS beat(4)6.95%
Max EPS beat(4)161.28%
EPS beat(8)7
Avg EPS beat(8)112.72%
EPS beat(12)11
Avg EPS beat(12)88.48%
EPS beat(16)14
Avg EPS beat(16)70.43%
Revenue beat(2)2
Avg Revenue beat(2)7.29%
Min Revenue beat(2)6.84%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)3.01%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)7.75%
Revenue beat(8)5
Avg Revenue beat(8)4.09%
Revenue beat(12)9
Avg Revenue beat(12)8.29%
Revenue beat(16)13
Avg Revenue beat(16)10.25%
PT rev (1m)42.68%
PT rev (3m)42.68%
EPS NQ rev (1m)8.34%
EPS NQ rev (3m)41.31%
EPS NY rev (1m)14.76%
EPS NY rev (3m)13.59%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)5.32%
Revenue NY rev (1m)3.31%
Revenue NY rev (3m)3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.89 | ||
| Fwd PE | 17.76 | ||
| P/S | 8.03 | ||
| P/FCF | 17.8 | ||
| P/OCF | 17.76 | ||
| P/B | 5.83 | ||
| P/tB | 5.89 | ||
| EV/EBITDA | 14.46 |
EPS(TTM)0.56
EY3.46%
EPS(NY)0.91
Fwd EY5.63%
FCF(TTM)0.91
FCFY5.62%
OCF(TTM)0.91
OCFY5.63%
SpS2.02
BVpS2.77
TBVpS2.74
PEG (NY)0.04
PEG (5Y)N/A
Graham Number5.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROCE | 19.28% | ||
| ROIC | 14.89% | ||
| ROICexc | 67.33% | ||
| ROICexgc | 70.07% | ||
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% | ||
| FCFM | 45.1% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score9
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.52 | ||
| Cap/Depr | 1.21% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.83% | ||
| Profit Quality | 154% | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 7.37 |
F-Score9
WACC7.63%
ROIC/WACC1.95
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
EPS Next Y743.2%
EPS Next 2Y218.19%
EPS Next 3Y124.5%
EPS Next 5Y70.13%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
Revenue Next Year18.56%
Revenue Next 2Y16.97%
Revenue Next 3Y15.79%
Revenue Next 5Y14.93%
EBIT growth 1Y448.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8148.86%
EBIT Next 3Y393.34%
EBIT Next 5YN/A
FCF growth 1Y414.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y421.82%
OCF growth 3YN/A
OCF growth 5YN/A
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to AUPH.
Can you provide the valuation status for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 7 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Undervalued.
What is the profitability of AUPH stock?
AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 5 / 10.
What are the PE and PB ratios of AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 28.89 and the Price/Book (PB) ratio is 5.83.
What is the expected EPS growth for AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Earnings per Share (EPS) of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 743.2% in the next year.